Community-based COVID-19 active case finding and rapid response in the Democratic Republic of the Congo: Improving case detection and response.


Journal

PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081

Informations de publication

Date de publication:
2023
Historique:
received: 11 11 2022
accepted: 25 04 2023
medline: 22 5 2023
pubmed: 18 5 2023
entrez: 18 5 2023
Statut: epublish

Résumé

A community-based coronavirus disease (COVID-19) active case-finding strategy using an antigen-detecting rapid diagnostic test (Ag-RDT) was implemented in the Democratic Republic of Congo (DRC) to enhance COVID-19 case detection. With this pilot community-based active case finding and response program that was designed as a clinical, prospective testing performance, and implementation study, we aimed to identify insights to improve community diagnosis and rapid response to COVID-19. This pilot study was modeled on the DRC's National COVID-19 Response Plan and the COVID-19 Ag-RDT screening algorithm defined by the World Health Organization (WHO), with case findings implemented in 259 health areas, 39 health zones, and 9 provinces. In each health area, a 7-member interdisciplinary field team tested the close contacts (ring strategy) and applied preventive and control measures to each confirmed case. The COVID-19 testing capacity increased from 0.3 tests per 10,000 inhabitants per week in the first wave to 0.4, 1.6, and 2.2 in the second, third, and fourth waves, respectively. From January to November 2021, this capacity increase contributed to an average of 10.5% of COVID-19 tests in the DRC, with 7,110 positive Ag-RDT results for 40,226 suspected cases and close contacts who were tested (53.6% female, median age: 37 years [interquartile range: 26.0-50.0)]. Overall, 79.7% (n = 32,071) of the participants were symptomatic and 7.6% (n = 3,073) had comorbidities. The Ag-RDT sensitivity and specificity were 55.5% and 99.0%, respectively, based on reverse transcription polymerase chain reaction analysis, and there was substantial agreement between the tests (k = 0.63). Despite its limited sensitivity, the Ag-RDT has improved COVID-19 testing capacity, enabling earlier detection, isolation, and treatment of COVID-19 cases. Our findings support the community testing of suspected cases and asymptomatic close contacts of confirmed cases to reduce disease spread and virus transmission.

Identifiants

pubmed: 37200322
doi: 10.1371/journal.pone.0278251
pii: PONE-D-22-31104
pmc: PMC10194859
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

e0278251

Subventions

Organisme : World Health Organization
ID : 001
Pays : International

Informations de copyright

Copyright: © 2023 Otshudiema et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Déclaration de conflit d'intérêts

The authors have declared that no competing interests exist.

Références

J Epidemiol Glob Health. 2022 Sep;12(3):316-327
pubmed: 35921045
N Engl J Med. 2020 Nov 26;383(22):e120
pubmed: 32997903
Lancet Infect Dis. 2021 Aug;21(8):1089-1096
pubmed: 33773618
J Infect. 2020 Dec;81(6):979-997
pubmed: 32858069
J Clin Microbiol. 2020 Jul 23;58(8):
pubmed: 32404480
N Engl J Med. 2020 Mar 5;382(10):970-971
pubmed: 32003551
Nat Hum Behav. 2020 Sep;4(9):964-971
pubmed: 32759985
Epidemiol Infect. 2020 Sep 11;148:e208
pubmed: 32912370
N Engl J Med. 2020 Mar 26;382(13):1199-1207
pubmed: 31995857
Infect Dis Poverty. 2019 Dec 3;8(1):99
pubmed: 31791412
PLoS One. 2021 Nov 19;16(11):e0257242
pubmed: 34797864
Lancet Glob Health. 2020 Apr;8(4):e488-e496
pubmed: 32119825
J Infect Dis. 2016 Sep 15;214(6):828-9
pubmed: 26984145
Proc Natl Acad Sci U S A. 2020 Jul 28;117(30):17513-17515
pubmed: 32632012
Sci Rep. 2021 Jul 6;11(1):13903
pubmed: 34230530
J Med Virol. 2021 Jan;93(1):137-138
pubmed: 32592498
China CDC Wkly. 2021 Jul 2;3(27):576-580
pubmed: 34594939
J Med Virol. 2020 Nov;92(11):2312-2313
pubmed: 32383182
JAMA. 2020 Apr 14;323(14):1406-1407
pubmed: 32083643
Trans R Soc Trop Med Hyg. 2015 Sep;109(9):545-52
pubmed: 26246249
Int J Tuberc Lung Dis. 2013 Apr;17(4):432-46
pubmed: 23485377
Lancet. 2020 Jul 4;396(10243):63-70
pubmed: 32505220
BMC Pediatr. 2022 Apr 2;22(1):172
pubmed: 35365104
Int J Infect Dis. 2020 May;94:133-138
pubmed: 32247826
Am J Trop Med Hyg. 2021 Feb 11;104(4):1179-1187
pubmed: 33571138
IJID Reg. 2022 Sep;4:33-41
pubmed: 35720960
Infect Dis Poverty. 2019 Oct 29;8(1):92
pubmed: 31661031
Lancet Infect Dis. 2021 Sep;21(9):e290-e295
pubmed: 33636148

Auteurs

John Otokoye Otshudiema (JO)

COVID-19 Response, World Health Organization, Kinshasa, Democratic Republic of the Congo.

Gervais Léon Tengomo Folefack (GLT)

COVID-19 Response, World Health Organization, Kinshasa, Democratic Republic of the Congo.

Justus M Nsio (JM)

COVID-19 Response, Ministry of Health, Kinshasa, Democratic Republic of the Congo.

Cathy H Kakema (CH)

COVID-19 Response, World Health Organization, Kinshasa, Democratic Republic of the Congo.

Luigino Minikulu (L)

COVID-19 Response, Ministry of Health, Kinshasa, Democratic Republic of the Congo.

Aimé Bafuana (A)

COVID-19 Response, Ministry of Health, Kinshasa, Democratic Republic of the Congo.

Joel B Kosianza (JB)

COVID-19 Response, World Health Organization, Kinshasa, Democratic Republic of the Congo.

Antoine K Mfumu (AK)

COVID-19 Response, World Health Organization, Kinshasa, Democratic Republic of the Congo.

Edith Nkwembe (E)

COVID-19 Laboratory and Epidemiology Team, National Institute of Biomedical Research, Kinshasa, Democratic Republic of the Congo.

Yannick Munyeku-Bazitama (Y)

COVID-19 Laboratory and Epidemiology Team, National Institute of Biomedical Research, Kinshasa, Democratic Republic of the Congo.

Sheila Makiala-Mandanda (S)

COVID-19 Laboratory and Epidemiology Team, National Institute of Biomedical Research, Kinshasa, Democratic Republic of the Congo.

Noé Guinko (N)

COVID-19 Response, World Health Organization, Kinshasa, Democratic Republic of the Congo.

Gisèle Mbuyi (G)

COVID-19 Response, Ministry of Health, Kinshasa, Democratic Republic of the Congo.

Jean-Marie K Tshilumbu (JK)

COVID-19 Response, World Health Organization, Kinshasa, Democratic Republic of the Congo.

Guy N Saidi (GN)

COVID-19 Response, World Health Organization, Kinshasa, Democratic Republic of the Congo.

Moreau-Serge Umba-di-Masiala (MS)

COVID-19 Response, World Health Organization, Kinshasa, Democratic Republic of the Congo.

Amos K Ebondo (AK)

COVID-19 Response, World Health Organization, Kinshasa, Democratic Republic of the Congo.

Jean-Jacques Mutonj (JJ)

COVID-19 Response, World Health Organization, Kinshasa, Democratic Republic of the Congo.

Serge Kalombo (S)

COVID-19 Response, World Health Organization, Kinshasa, Democratic Republic of the Congo.

Jad Kabeya (J)

COVID-19 Response, World Health Organization, Kinshasa, Democratic Republic of the Congo.

Taty K Mawanda (TK)

COVID-19 Response, World Health Organization, Kinshasa, Democratic Republic of the Congo.

Faustin N Bile (FN)

COVID-19 Response, World Health Organization, Kinshasa, Democratic Republic of the Congo.

Gaby K Kasereka (GK)

COVID-19 Response, World Health Organization, Kinshasa, Democratic Republic of the Congo.

Placide Mbala-Kingebeni (P)

COVID-19 Laboratory and Epidemiology Team, National Institute of Biomedical Research, Kinshasa, Democratic Republic of the Congo.

Steve Ahuka-Mundeke (S)

COVID-19 Laboratory and Epidemiology Team, National Institute of Biomedical Research, Kinshasa, Democratic Republic of the Congo.

Humphrey Cyprian Karamagi (HC)

Data Analytics and Knowledge Management, World Health Organization Regional Office for Africa, Brazzaville, Democratic Republic of Congo.

Karl Njuwa Fai (KN)

Research Arm - MSF Epicentre, Yaoundé, Cameroon.

Amédée Prosper Djiguimde (AP)

COVID-19 Response, World Health Organization, Kinshasa, Democratic Republic of the Congo.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH